Vineeta Kumar is a Nephrology physician affiliated with University of Alabama at Birmingham. OpenAlex indexes 156 publications with 2,396 citations (h-index 26); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1717 6th Ave S
Birmingham, AL 352331801
Telephone
800-822-8816Registry record last updated 6 Feb 2024.
Clinical trials
- Promoting Increases in Living Donation Via Tele-navigation (PILOT)
Sponsor: University of Alabama at Birmingham
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
8 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Novartis Pharmaceuticals CorporationProgram year20258 payments$10,284openpaymentsdata.cms.gov ↗
- Apellis Pharmaceuticals, Inc.Program year20252 payments
- Alexion Pharmaceuticals, Inc.Program year20252 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
40.9%Beta blocker10.5%Carvedilol84%Metoprolol Succinate16%Part D<11 patientsCalcium channel blocker9.1%Amlodipine Besylate62%Nifedipine Er39%Part D≥20 patients+ 6 more classes in this area
Anti-infectives
25.4%Short-acting sulfonamides17.2%Sulfamethoxazole-Trimethoprim100%Part D≥56 patientsCytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor2.8%Valganciclovir Hcl100%Part D≥14 patients+ 3 more classes in this area
Metabolism & gastrointestinal
24.6%Corticosteroid11.7%Prednisone100%Part D≥35 patientsProton pump inhibitor9.3%Pantoprazole Sodium85%Omeprazole15%Part D<11 patients+ 1 more class in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- C5 inhibition with eculizumab prevents thrombotic microangiopathy in a case series of pig-to-human kidney xenotransplantation
Journal of Clinical Investigation
2024 - Spatiotemporal immune atlas of a clinical-grade gene-edited pig-to-human kidney xenotransplant
Nature Communications
2024 - Should Transplant Nephrology Pursue Recognition from the Accreditation Council for Graduate Medical Education (ACGME)?
Clinical Journal of the American Society of Nephrology
2024
Similar KOLs
Other experts from the same institution or the same specialty.
Vera Bittner
University of Alabama at Birmingham
Richard Whitley, MD
University of Alabama at Birmingham
David Standaert, MD, PhD
University of Alabama at Birmingham
Erik Roberson
University of Alabama at Birmingham
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”